Grünenthal Appoints Prof. Dr. Uli Brödl as Chief Scientific Officer
Grünenthal has made a significant move by appointing Prof. Dr. Uli Brödl as its Chief Scientific Officer (CSO) and a member of the Corporate Executive Board. He is set to begin his journey with Grünenthal effective February 1, 2025. This decision underscores the company's commitment to strengthening its leadership in pharmaceutical innovation.
Uli Brödl's Impressive Background
With over 15 years of experience in the pharmaceutical industry, Uli Brödl has made a name for himself at Boehringer Ingelheim, where he held the position of Corporate Senior Vice President, overseeing Global Clinical Development & Operations. His expertise includes managing clinical development activities across multiple therapeutic areas, which showcases his ability to bridge the gap between research and commercial functions.
During his tenure, he played a pivotal role in the successful development of various medications, such as Empagliflozin, which is an oral treatment for diabetes. His previous experience also includes leading Boehringer Ingelheim's Canadian medical organization, where he gained valuable insights into market dynamics. Furthermore, Uli Brödl's entrepreneurial spirit shines through his initiative to co-found the BI Canada Incubator, aimed at fostering innovative healthcare solutions.
Educational Achievements
Uli Brödl is not only a seasoned professional but also an accomplished academic. He graduated as a Medical Doctor from Ludwig-Maximilians University Munich and holds certifications as an internist and endocrinologist. Additionally, he serves as an Adjunct Professor of Internal Medicine, reinforcing his involvement in the ongoing education and development of future medical professionals.
Grünenthal's Commitment to Innovation
In his own words, Uli Brödl expressed what drew him to Grünenthal: "The unique focus on improving the quality of life of underserved patients suffering from pain attracted me to Grünenthal." His enthusiasm reflects a shared passion for innovation that aligns with Grünenthal's mission to lead in pain management.
CEO's Confidence in Uli Brödl's Leadership
Gabriel Baertschi, the CEO of Grünenthal, spoke highly of Uli Brödl's appointment, stating, "With Uli, we have been able to attract an excellent leader. His extensive experience in R&D and commercial functions, combined with Uli's drive to bring innovative medicines to patients, will help us propel our vision of a world free of pain." This reinforcement from leadership illustrates the tremendous potential for progress and enhances the company's path forward.
About Grünenthal
Grünenthal stands out as a global leader in the field of pain management and related diseases. As a science-driven and fully integrated pharmaceutical enterprise, Grünenthal proudly carries a history of delivering advanced treatments and cutting-edge technologies to patients across the globe. Their foundational belief is to change lives positively, which reflects their deep-rooted passion for innovation.
The company's headquarters is situated in Aachen, reaching out with affiliates in 27 countries across Europe and Latin America. Their products are accessible in approximately 100 countries worldwide. In 2023, Grünenthal proudly employed around 4,400 individuals and generated revenues of €1.8 billion, highlighting its impactful role in the healthcare sector.
Frequently Asked Questions
Who is Prof. Dr. Uli Brödl?
Prof. Dr. Uli Brödl is the newly appointed Chief Scientific Officer of Grünenthal, with over 15 years of experience in the pharmaceutical industry.
What was Uli Brödl's previous position?
Before joining Grünenthal, Uli Brödl was Corporate Senior Vice President at Boehringer Ingelheim, where he led Global Clinical Development & Operations.
What educational background does Uli Brödl have?
Uli Brödl graduated as a Medical Doctor from Ludwig-Maximilians University Munich and is a board-certified internist and endocrinologist.
What is Grünenthal's main focus?
Grünenthal's main focus is on improving the quality of life for patients suffering from pain through research, development, and innovation.
Where is Grünenthal headquartered?
Grünenthal is headquartered in Aachen, Germany, and has a presence in 27 countries worldwide.
